Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Partners Launch Neviah Genomics
by Ann M. Thayer
July 2, 2012
| A version of this story appeared in
Volume 90, Issue 27
Merck Serono and Compugen have established Neviah Genomics, a company focused on the discovery and development of biomarkers to predict the toxicity of lead drug candidates early in development. The start-up will be funded initially by Merck Serono Ventures and operate out of the Merck Serono Israel Bioincubator. In return for providing technology, Compugen will receive an ownership stake in Neviah and the right to royalties from potential sales. The two companies successfully collaborated in 2009 on the discovery of biomarker signatures for drug toxicity.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter